Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 54 for “"modified release"”.

  1. Modified-Release Formulations for Cancer Therapy

    … (I3A), a protein kinase C agonist. The in vitro release study, in vitro cytotoxicity assay, and the in vivo pharmacokinetics demonstrated the potential MVLs to overcome I3A’s poor solubility, sustain drug release, and prevent the rapid clearance from the injection site. The third chapter …

    ku Repository record for Modified-Release Formulations for Cancer Therapy (opens in a new tab)

  2. Modified release formulations manufactured by hot-melt extrusion

    … overcome poor drugs water-solubility. Sustained release amorphous solid dispersions are challenging to formulate due to the low extent of supersaturation, the gelation phenomenon around the matrix and recrystallization. Different polymeric carriers for hot-melt-extruded amorphous tablets were …

    texas Repository record for Modified release formulations manufactured by hot-melt extrusion (opens in a new tab)

  3. Modified Release of Agglomerated Nano-Particles for Pulmonary Drug Delivery

    … prepared agglomerated nanoparticles having modified drug release properties with an aerodynamic particle size suitable for delivery to the lungs.|First, a water-soluble model drug was formulated as microencapsulated dry powders using aqueous spray drying with a fluid nozzle. The spray dried …

    creighton Repository record for Modified Release of Agglomerated Nano-Particles for Pulmonary Drug Delivery (opens in a new tab)

  4. Thermal processing of synthetic waxes for modified release solid dosage forms

    The aim of this thesis was to investigate the pharmaceutical application of a range of synthetic wax esters, namely Syncrowax™ BB4, ERLC, HGLC and HRC. Thermogravimetric analysis of the four grades showed that the materials were thermally stable at operating temperatures up to l 50°C. Differential …

    qu-belfast Repository record for Thermal processing of synthetic waxes for modified release solid dosage forms (opens in a new tab) Download PDF for Thermal processing of synthetic waxes for modified release solid dosage forms (opens in a new tab)

  5. Influence of modified release excipients on ketoprofen release from chitosan particles

    Controlled release formulations offer many advantages over conventional dosage forms. These include reduced plasma fluctuations and improved patient comp1i:nce. Complex controlled release formulations such as those with enteric release properties, often require additional steps in the production …

    nwu-za Repository record for Influence of modified release excipients on ketoprofen release from chitosan particles (opens in a new tab)

  6. Performance of various oral modified release dosage forms in hydroethanolic media

    The safety and efficacy of modified release drug formulations depend on their ability to allow a reproducible release that is affected as little as possible by external influences. These influences include the prandial status of a patient, the gastrointestinal motility as well as the concomitant …

    fu-berlin Repository record for Performance of various oral modified release dosage forms in hydroethanolic media (opens in a new tab)

  7. DESIGN AND DEVELOPMENT OF CAPSULAR MOLDED DEVICES FOR MODIFIED RELEASE OF DRUGS

    … focused on the formulation and manufacturing of modified-release drug delivery systems employing injection molding (IM) technique. IM is based on the injection, under high pressure and temperature, of thermoplastic materials into a mold. The interest in applying IM as well as micromolding (μIM) …

    milano Repository record for DESIGN AND DEVELOPMENT OF CAPSULAR MOLDED DEVICES FOR MODIFIED RELEASE OF DRUGS (opens in a new tab)

  8. CAPSULAR DEVICES FOR ORAL MODIFIED RELEASE OF DRUGS PREPARED BY INJECTION MOLDING

    … giving rise to the expected pulsatile release performance, confirmed by in vivo data. The PhD project was undertaken aiming at improving the robustness and versatility of the ChronocapTM device as well as enhancing the industrial scalability of its manufacturing process. For this …

    milano Repository record for CAPSULAR DEVICES FOR ORAL MODIFIED RELEASE OF DRUGS PREPARED BY INJECTION MOLDING (opens in a new tab)

  9. Cassava starch as modified release excipient in selected gliclazide oral dosage forms

    … solid oral dosage forms resulting in different release mechanisms. Drug release is an important consideration during dosage form design especially for drugs with short half-lives. These types of drugs require regularly timed dosing intervals. More dose intervals can impede the adherence to …

    nwu-za Repository record for Cassava starch as modified release excipient in selected gliclazide oral dosage forms (opens in a new tab)

  10. Solubility/Bioavailability Enhancement and Modified Release Formulations of Poorly Water-Soluble Drugs

    … a basic poorly water-soluble drug, the release in 0.1 N HCl was fast and complete within 30 min. Furthermore, the supersaturated solutions were stable for more than 24 h and were not affected by changing the pH of the medium from 1.0 to 6.8. Extended and complete drug release was also …

    fu-berlin Repository record for Solubility/Bioavailability Enhancement and Modified Release Formulations of Poorly Water-Soluble Drugs (opens in a new tab)

  11. Development of a Novel Vaccine Adjuvant System Utilizing an In Situ Implant System to Modified Release

    Pulsatile release formulations for single dose vaccines have been studied for many years because of the advantages that they may provide to vaccine administration with a single dose instead of prime and booster shots. The aim of this work is to develop novel formulations based on an In Situ Implant …

    tenn-hsc Repository record for Development of a Novel Vaccine Adjuvant System Utilizing an In Situ Implant System to Modified Release (opens in a new tab)

  12. Συστηματική ανασκόπηση για τα βραδείας και παρατεταμένης αποδέσμευσης σκευάσματα υδροκορτιζόνης (modified-release hydrocortisone, MR-HC) στη θεραπεία της κλασικής μορφής συγγενούς υπερπλασίας των επινεφριδίων

    ΕΙΣΑΓΩΓΗ: Η Συγγενής Υπερπλασία των Επινεφριδίων (ΣΥΕ) λόγω ανεπάρκειας της 21-υδροξυλάσης είναι μία γενετική νόσος που κληρονομείται με αυτοσωματικό υπολειπόμενο χαρακτήρα. Η ΣΥΕ χαρακτηρίζεται από ανεπαρκή παραγωγή κορτικοστεροειδών και αλατοκορτικοειδών και υπερπαραγωγή επινεφριδιακών …

    athens Repository record for Συστηματική ανασκόπηση για τα βραδείας και παρατεταμένης αποδέσμευσης σκευάσματα υδροκορτιζόνης (modified-release hydrocortisone, MR-HC) στη θεραπεία της κλασικής μορφής συγγενούς υπερπλασίας των επινεφριδίων (opens in a new tab)

  13. «In vitro μελέτες τροποποιημένης αποδέσμευσης της ορμόνης μελατονίνης από στερεές φαρμακοτεχνικές μορφές του PLA και παραγώγων του» «The hormone melatonin: in vitro modified release studies from PLA and PLA-based solid pharmaceutical formulations»

    Η μελατονίνη (Ν-ακετυλο-5-μεθοξυθρυπταμίνη) είναι μία ενδοκρινής ορμόνη του ανθρώπινου οργανισμού, καθώς και των άλλων θηλαστικών, που συντίθεται στην επίφυση του εγκεφάλου από το αμινοξύ θρυπτοφάνη και με βάση τον κιρκαδιακό ρυθμό, που λειτουργεί με περιοδικότητα 24 ωρών. Η μελατονίνη θεωρείται το …

    athens Repository record for «In vitro μελέτες τροποποιημένης αποδέσμευσης της ορμόνης μελατονίνης από στερεές φαρμακοτεχνικές μορφές του PLA και παραγώγων του» «The hormone melatonin: in vitro modified release studies from PLA and PLA-based solid pharmaceutical formulations» (opens in a new tab)

  14. Population pharmacokinetic modelling of an investigational prodrug

    … of linking this model to previous works on a modified release form of this prodrug. The data used to create this model were provided from a phase I study. Concentration-time measurements were available for three compounds; the prodrug, the metabolite and the active compound. The model …

    liege Repository record for Population pharmacokinetic modelling of an investigational prodrug (opens in a new tab) Download PDF for Population pharmacokinetic modelling of an investigational prodrug (opens in a new tab)

  15. Development of lipid matrix tablets containing a double fixed dose combination of artemisone and lumefantrine

    … the bioavailability (Xia et al., 2014). Modified release of the drugs from the lipid-matrices is another advantage of incorporating drugs into a lipid-matrix (Nisha et al., 2012). Drug releases from lipid-matrices occur by means of erosion and/or pore diffusion -- in this study pore …

    nwu-za Repository record for Development of lipid matrix tablets containing a double fixed dose combination of artemisone and lumefantrine (opens in a new tab)

  16. Obtenção e avaliação do potencial imunoadjuvante de nanopartículas de quitosana na produção de antissonoros contra venenos de serpentes e escorpiões

    … characterization and evaluation of the release profile demonstrated that it is a modified release system. The stability of different systems was evaluated for 7 weeks, observing a greater stability of the systems associated with venoms. Experimental animals were immunized subcutaneously …

    brazil-ufrn Repository record for Obtenção e avaliação do potencial imunoadjuvante de nanopartículas de quitosana na produção de antissonoros contra venenos de serpentes e escorpiões (opens in a new tab)

  17. Παρασκευή και αξιολόγηση φαρμακευτικών προϊόντων τροποποιημένης αποδέσμευσης για χορήγηση σε ανθρώπους και σκύλους

    … aim of this investigation is to compare the release behavior of multiple-unit modified-release formulation (‘tablets in capsule’) of two active ingredients, mesalazine and theophylline, by the use of simple or enteric-coated capsules, with either dextran or pectin as excipients, with respect …

    greece Repository record for Παρασκευή και αξιολόγηση φαρμακευτικών προϊόντων τροποποιημένης αποδέσμευσης για χορήγηση σε ανθρώπους και σκύλους (opens in a new tab)

  18. Tools for accelerating the development of amorphous drug solid dispersions: case example, tacrolimus

    … simple eutectic mixtures to complex systems with modified release characteristics. ASDs exhibit the ability to increase the apparent solubility of APIs in the gut lumen by allowing the delivery of the API in a high energy form, most frequently, in the amorphous state. However, a high energy form …

    greece Repository record for Tools for accelerating the development of amorphous drug solid dispersions: case example, tacrolimus (opens in a new tab)

  19. Desenvolvimento de formulações cosméticas contendo sistema multicomponente com ácido ferúlico: caracterização e ensaios in vitro de liberação cutânea

    … photostable after irradiation. In in vitro skin release studies, formulations with isolated FA showed greater and faster release, whereas CF promoted slower and modified release, indicating that complexation of the active ingredient and the formulation modulate the availability and flux of FA. …

    brazil-ufrn Repository record for Desenvolvimento de formulações cosméticas contendo sistema multicomponente com ácido ferúlico: caracterização e ensaios in vitro de liberação cutânea (opens in a new tab)

Page 1 of 3